Aeglea BioTherapeutics reports Q1 2023 net loss of $18.4M; cash at $39.8M

Spyre Therapeutics, Inc.

2023-Q1 EPS reported -$0.20 revenue$198,000

Cash, equivalents, marketable securities, restricted cash totaled $39.8M as of March 31, 2023.
Revenue of $0.2M from Immedica Pharma license/supply agreement for pegzilarginase in Europe/Middle East.
R&D expenses fell to $13.8M from $17.0M; G&A expenses fell to $5.2M from $8.8M year-over-year.
Net loss improved to $18.4M from $24.4M in Q1 2022; includes $1.7M non-cash stock compensation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Spyre Therapeutics, Inc. reported first quarter 2023 results: revenue $0.2 million, net income Net loss totaled $18.4 million.

Period: first quarter 2023
Revenue: $0.2 million
Net income: Net loss totaled $18.4 million
Result: reported results

Exact text from the filing

31, 2023, Aeglea had available cash and cash equivalents, marketable securities and restricted cash of $39.8 million. Aeglea recognized development fee and royalty revenues of $0.2 million in the first quarter of 2023, as a result of its license and supply agreement with Immedica Pharma AB for the commercial rights to pegzilarginase in Europe and several countries

View on SEC.gov

Browse all earnings releases →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020819

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.